Benlysta (belimumab) is a prescription medication used to treat active systemic lupus erythematosus (SLE) and active lupus nephritis. It can be given as an intravenous (IV) infusion or an injection ...
Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.
The European Commission has approved a new subcutaneous formulation of belimumab (Benlysta, GlaxoSmithKline) as adjunctive treatment for adults with active, autoantibody-positive systemic lupus ...
MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...
The European Medicines Agency (EMA) has recommended approval of a self-injectable form of belimumab (Benlysta, GlaxoSmithKline) as an add-on therapy for adults with the most common form of lupus, ...
The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...
The Food and Drug Administration (FDA) has expanded the approval of Benlysta (belimumab) to include pediatric patients 5 to 17 years of age with active lupus nephritis who are receiving standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results